中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

13 records (took 0.023 seconds)

    IDENTIFICATION OF METASTASIS-SPECIFIC MIRNA AND HYPOMETHYLATION SIGNATURES IN HUMAN COLORECTAL CANCER
    2.
    发明申请
    IDENTIFICATION OF METASTASIS-SPECIFIC MIRNA AND HYPOMETHYLATION SIGNATURES IN HUMAN COLORECTAL CANCER 审中-公开
    METASTASIS-SPECIFIC MIRNA和HYPOMETHYLATION SIGNATURES在人类癌症中的鉴定

    公开(公告)号：US20150072341A1

    公开(公告)日：2015-03-12

    申请号：US14367827

    申请日：2012-12-21

    Applicant: BAYLOR RESEARCH INSTITUTE

    Inventor： Ajay Goel ,  C. Richard Boland ,  Keun Hur

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2525/207 ,  C12Q2600/154 ,  C12Q2600/178

    Abstract: The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

    Abstract translation: 本发明包括通过将生物样品中的Alu重复甲基化水平与来自人类受试者的正常非癌性样品的Alu重复甲基化对照水平进行比较来诊断或检测人类受试者中的结肠直肠癌转移的方法和生物标志物，其中a Alu重复甲基化水平的降低指示结肠直肠癌和结肠直肠癌转移。 本发明还包括用于通过测定样品中let-7i，miR-10b，miR-320a和miR-221的表达水平来诊断或检测人类受试者中的结肠直肠癌（CRC）转移的方法和生物标志物 或更多的生物样品; 并将样品中let-7i，miR-10b，miR-320a和miR-221的表达水平与let-7i，miR-10b，miR-320a和miR-221的表达水平与正常 结肠直肠组织，其中至少使let-7i或miR-320a的高表达指示CRC的良好预后，而miR-10b或miR-221中的至少一种的低表达指示良好的预后 用于CRC或CRC转移。

    Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer
    3.
    发明授权
    Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer 有权

    公开(公告)号：US10519506B2

    公开(公告)日：2019-12-31

    申请号：US14367827

    申请日：2012-12-21

    Applicant: Baylor Research Institute

    Inventor： Ajay Goel ,  C. Richard Boland ,  Keun Hur

    IPC: C12Q1/68 ,  C12Q1/6886

    Abstract: The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

    Methods for diagnosing and treating esophageal cancer
    6.
    发明授权
    Methods for diagnosing and treating esophageal cancer 有权

    公开(公告)号：US11603566B2

    公开(公告)日：2023-03-14

    申请号：US16322380

    申请日：2017-08-04

    Applicant: BAYLOR RESEARCH INSTITUTE

    Inventor： Ajay Goel ,  Jinsei Miyoshi

    IPC: C12Q1/68 ,  C12Q1/6886 ,  A61P35/04 ,  A61K33/243 ,  A61K31/337 ,  A61K31/351 ,  A61K31/513 ,  C12Q1/02

    Abstract: The current disclosure relates to therapeutic treatments and diagnostic methods for esophageal cancer based on the expression level of biomarker miRNAs. Aspects of the disclosure relate to a method of treating esophageal cancer (EC) in a patient, said method comprising: diagnosing the patient with esophageal cancer when the patient is determined to have an elevated or decreased level of expression of one or more miRNAs selected from mir-15b, miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir-223, mir-224, mir-335, mir-338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir-3648, and let-7i in a sample from a patient relative to the expression level of the one or more miRNAs in a control sample; and administering an effective amount of an esophageal treatment to the diagnosed patient.

    MiR-320e and colorectal cancer
    7.
    发明授权
    MiR-320e and colorectal cancer 有权

    公开(公告)号：US10260105B2

    公开(公告)日：2019-04-16

    申请号：US15120052

    申请日：2015-02-18

    Applicant: BAYLOR RESEARCH INSTITUTE

    Inventor： Ajay Goel ,  Lucia Perez-Carbonell ,  C. Richard Boland

    IPC: C12Q1/68 ,  A61K31/513 ,  C12N15/113 ,  G06F19/00 ,  C12Q1/6886 ,  G16H40/63 ,  G16H10/60

    Abstract: Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients. Embodiments provide predictive, prognostic and/or diagnostics methods by identifying miRNAs that are useful for clinical management of cancer patients, particularly colorectal cancer patients or patients at risk or determined to have colorectal cancer. Methods and compositions are based, in part, on the discovery that expression of certain miRNAs in cancer patients is associated with advancing cancer stages and/or can predict the responsiveness of cancer therapy, and can, therefore, provide basis for designing treatment strategies. In particular embodiments, the miRNA molecule is miR-320, particularly miR-320e.

Patent Agency Ranking